Cash Flow Statement

Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Zentalis Pharmaceuticals (ZNTL) Other financing activities (2024)

Zentalis Pharmaceuticals has reported Other financing activities over the past 1 years, most recently at $241000.0 for Q1 2024.

For Q1 2024, Other financing activities changed N/A year-over-year to $241000.0; the TTM value through Sep 2024 reached $241000.0, changed N/A, while the annual FY2020 figure was $18.4 million, 39952.17% up from the prior year.
Other financing activities for Q1 2024 was $241000.0 at Zentalis Pharmaceuticals.
Over five years, Other financing activities peaked at $241000.0 in Q1 2024 and troughed at $241000.0 in Q1 2024.